rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Biomechanical Investigation of Symptomatic FAI and Two Groups of Asymptomatic Controls
Status: Recruiting

Femoroacetabular impingement (FAI) is an orthopaedic condition that is primarily characterized by the presence of anatomic bony abnormalities in the femoral head and/or the acetabulum resulting in an abnormal contact between the two during hip motion, especially in positions of increased hip flexion and rotation, ultimately leading to hip pain. Unfortunately, a FAI diagnosis is frequently only made once symptoms have become severe to an extent that they limit everyday life activities. Moreover, another important aspect that has been consistently overlooked in past FAI movement studies is the influence muscle strength and activation can have on movement pattern and symptom presentation. The diagnosis and management of FAI needs to be addressed through a more wholesome investigation of the biomechanical influence on the manifestation of symptoms.

This project aims to further unravel the link between spinopelvic anatomy, its biomechanical contribution to femoro-pelvic motion and the manifestation of femoroacetabular impingement in adult male population. By, for the first time, integrating three-dimensional (3D) instrumented motion analysis with state-of-the-art full-body biplanar X-ray imaging (EOS imaging, Paris France), we will more specifically investigate the presence of an association between spinopelvic kinematics and the link to symptomatic FAI morphology, as well as investigate the presence of differences in these measures between symptomatic and asymptomatic subjects with comparable femoral morphology.

Eligibility:
- EligibilityCriteria: Exclusion Criteria:  - Participants in all three study groups will be excluded if x-ray scans shows a pincer FAI morphology or radiological sign of osteoarthritis.  Inclusion Criteria:  All participants will be males aged between 21 and 35 years old.  For symptomatic CAM-FAI patients  The presence of CAM-FAI morphology at the head-neck junction of the femur Alpha angle >60 Reduced hip internal rotation (IR<15)  For asymptomatic CAM controls:  1. Exhibit asymptomatic CAM on x-ray scansAlpha angle >60  For Healthy control group:  Exhibit no symptoms or abnormal morphologies of the proximal femur (Alpha angle >60 , IR>15). - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Male - MinimumAge: 21 Years - MaximumAge: 35 Years - StdAgeList: Adult
Neuromodulation With Spinal Stimulation Methods
Status: Recruiting

This is a pilot research study to test the protocols needed for transcutaneous spinal electrical stimulation in persons living with spinal cord injury (SCI). Up to 24 participants will be enrolled. A variety of stimulation parameters and outcome measures will be assessed.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  spinal cord injury C4 to L4 ability to understand and follow directions  Exclusion Criteria:  history of seizures, head injury, concussion, unexplained loss of consciousness or if they lived with an implanted cochlear stimulator, brain/neurostimulator, cardiac pacemaker, medication infusion device or live with metal implants in their body or if they are pregnant. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Tumor Microenvironment in Ovarian Cancer
Status: Recruiting

A detailed understanding of molecular mechanism of cancer genesis is fundamental to develop innovative and personalized therapies. The new frontier in biomedical research is represented by organoids, a three-dimensional cell culture system obtained from a tissue fragment that accurately reproduces the essential properties of the original tissue in vitro, which could provide a valuable model for explanation of ovarian cancers pathogenesis and will allow to predict the response to a specific therapy. With this research project, we expect to generate ovarian cancer organoids to characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and/or microbial-derived molecules).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age > 18 years Age < 80 years Serous ovarian carcinoma FIGO Stage III-IV  Exclusion Criteria:  Ongoing or suspended immunosuppressive therapy within the last 6 months Congenital or acquired immunodeficiency Immunosuppressive state Administration of chemotherapy for another neoplasm in the past 12 months Non-epithelial ovarian tumors Patients not undergoing surgical intervention BMI > 30 Absence of Informed Consent - HealthyVolunteers: No - Gender: Female - GenderBased: Yes - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with primary diagnosis (t=0) of epithelial ovarian cancer (stage III and IV according to FIGO) - SamplingMethod: Non-Probability Sample
Immediate Effects of Open and Closed Kinetic Chain Exercises on Upper Extremity in Stroke Patients.
Status: Recruiting

Stroke is a sudden disruption of blood flow to the brain, resulting in physical and mental disabilities. It's a global health issue affecting millions each year, often leading to paralysis, altered muscle tone, and loss of motor control and balance. This study aims to examine the immediate effects of open and closed kinetic chain activites on upper extremity spasticity and motor dexterity in hemiplegic patients. This study will be conducted simultaneously at İstinye University Hospital Medical Park Gaziosmanpaşa and İstinye University Physiotherapy and Rehabilitation Application and Research Center (İSÜFİZYOTEM). 50 stroke patients will be included in the study, and all participants will be asked to sign an informed consent form. At the beginning of the session, all participants will be evaluated for their socio-demographic characteristics by a questionnaire created by the researchers, muscle viscoelastic properties by MyotonPRO, upper extremity muscle tone by Modified Ashworth Scale, upper extremity motor dexterity by Box and Block Test, and upper extremity joint range of motion by goniometer and by a phone application named as PhysioMaster. After the assessment, participants will be randomly assigned to two groups: open kinetic chain activity group and closed kinetic chain activity group. After performing the exercises, all evaluations will be conducted again. Thus, the aim is to understand the immediate effects of two different group exercises on the evaluated parameters.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Stroke diagnosis; Hemiplegia; Subacute&chronic phase (more than 3 months); Brunnstrom 3-4-5; Unsupported sitting ability; Being volunteer.  Exclusion Criteria:  Having Botox within the last 6 months; 4 according to Modified Ashworth Scale; Other neurological diagnosis other than stroke. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy
Status: Not yet recruiting

A randomized controlled trial comparing the effect of local ablative MR-guided radiotherapy (MRgRT) after systemic therapy with current standard treatment alone, on health-related quality of life in patients with locally advanced pancreatic cancer (LAPC).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Pathology proven pancreatic ductal adenocarcinoma (PDAC); At least two (preferably four) months systemic therapy with (m)FOLFIRINOX and/or gemcitabine + nab-paclitaxel; or eligibility for chemotherapy but no initiation of chemotherapy based on patients' wish; No option for surgical resection, either because anatomical irresectability based on the surgeon's judgement (assessed on imaging or during explorative laparotomy) and/or frailty (unfit for surgery or chemotherapy) and/or no surgery based on patient's wish. No evidence of distant metastatic disease progression, evaluated by CT Thorax / Abdomen / Pelvis and/or PET-CT scan; Performance status WHO 0-2.  Exclusion Criteria:  Contra-indications for MRI or CT with an intravenous contrast agent according to the protocol of the local radiology and/or radiotherapy departments  Contraindications for MRgRT, as determined by the involved expert radiation oncologists of the Consortium <18 years old Pregnancy - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease
Status: Recruiting

This exploratory trial is to prove the tolerability and safety of VGN-R08b to treat infants with type II Gaucher disease.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Infants with age of ≤24 months. Historical diagnosis of Gaucher disease confirmed by GCase enzyme activity test, and with GBA1 biallelic mutations. Neurological signs and/or symptoms consistent with diagnosis of GD2. Parent(s)/legal guardian(s) of subject must give their consent for subject to enroll in the study. Parent(s)/legal guardian(s) of the subject must agree to comply with the requirements of the study, including providing disease information and support disease assessment of symptoms.  Exclusion Criteria:  Diagnosis of a significant CNS disease other than GD2 that may be a cause for the patient's GD symptoms or may confound study objectives. Achieved independent gait. Severe visceral symptoms of GD which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study. Clinically active infection (including HIV, HBV, HCV or syphilis). For those receiving enzyme replacement therapy and/or substrate reduction therapy and/or ambroxol for Gaucher disease, stable treatment ≤2 months before enrollment. Use of strong inhibitors or inducers of cytochrome CYP3A4 or P-glycoprotein (P-gp) medications, herbals, or over-the-counter agents. Any type of prior gene or cell therapy. Immunizations (live vaccines) in the prior 4 weeks. Use of systemic immunosuppressant or corticosteroid therapy other than protocol-specified (topical preparations for dermatological conditions are allowed). Patients with anti-AAV9 neutralizing antibody titer over 1:5. Brain MRI (magnetic resonance imaging) showing clinically significant abnormality considered to prevent intracisternal injection. Contraindication to sedation during surgery or imaging studies (PET). Presence of other significant medical conditions that would create an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 0 Months - MaximumAge: 24 Months - StdAgeList: Child
Spiden Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)
Status: Recruiting

This is a single-centre, multiple sequential-cohort, open study.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or female trial participant with clinically diagnosed type 1 or type 2 diabetes for at least 1 year. Age between 18 and 65 years, both inclusive. Treated with basal insulin or basal insulin and oral antidiabetic drugs (OADs; type 2 only), multiple dosing insulin therapy (MDI), continuous subcutaneous insulin infusion (CSII) or a hybrid closed loop system.  Exclusion Criteria:  Known or suspected hypersensitivity to any of the components of the Spiden Clinical Demo 2.0. Trial participant with any injury, infection, atypical skin condition (e.g., hyperkeratosis, hyperpigmentation) of or tattoo on the wrists. Presence or history of a cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias or clinically significant conduction disorders. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Endotypic Stability in CRS
Status: Recruiting

A Case control study with 150 cases and 50 controls will be conducted. Immunologic (cytokines measurements in nasal secretions and sinonasal tissues), histopathologic (tissue eosinophilia) and clinical parameters (Lund-Mackay and Lund-Kennedy score, lung function tests), surveys (SNOT- 22, SF-36 quality of life survey) will be compared between different groups of patients

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients with Chronic sinusitis (with or without polyps) Undergoing endoscopic sinus surgery during the study period More than 18 years No chronic illness/ malignancy - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 100 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with Chronic sinusitis (with or without polyps) undergoing endoscopic sinus surgery. - SamplingMethod: Non-Probability Sample
Postoperative Difficult-to-Heal Wounds of Clinical Trial Registration
Status: Not yet recruiting

This study aims to investigate the effectiveness of an optimized care management protocol for refractory postoperative wounds based on the TIME CDST tool. Through a randomized controlled trial approach, the investigators will conduct a rigorous comparative analysis of the experimental group and the control group. The intervention group will receive an intervention plan based on the TIME CDST tool led by wound specialist nurses at each dressing change, while the control group receive a routine wound care program of wound cleaning and dressing changes at each dressing change. The main research objective is to evaluate the superiority of the experimental group compared with the control group in terms of wound healing time, healing quality, and patient satisfaction. Through the implementation of this study, the investigators expect to provide an effective optimization scheme for the management of refractory postoperative wounds in clinical practice, thereby improving patient outcomes and quality of life.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  age ≥18 years; wound healing time after surgery more than 2 weeks; patients have normal cognitive and communication skills; patients are able to cooperate with relevant nursing measures; patients voluntarily participate in this trial and sign the informed consent form.  Exclusion Criteria:  patients are severe malnutrition or obesity; patients combine with other infectious diseases; patients with comorbid malignancies, severe endocrine and hematologic diseases; patients combine with heart, liver, kidney and other organ dysfunction; patients combine with autoimmune diseases. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Analysis of TPE Treatments With multiFiltratePRO
Status: Not yet recruiting

Analysis of therapeutic plasma exchange (TPE) treatments to assess the performance of the TPE mode of multiFiltratePRO based on the successful exchange of plasma from whole blood. The multiFiltratePRO is a device for extracorporeal blood purification treatments.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Body weight ≥40kg irrespective of the age Patients with indication for TPE treatment according to ASFA guideline Patients have been treated with TPE between January 2019 and October 2023 Availability of at least 50% of the parameters to be documented for the patient  Exclusion Criteria:  Participation in an interventional clinical study during the retrospectively collected TPE treatment data Previous documentation within this study Simultaneous use of another filter for additional therapy form - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with indication for TPE treatment according to ASFA (American Society for Apheresis) guideline treated with TPE between January 2019 and October 2023. - SamplingMethod: Non-Probability Sample
A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of Severe Hepatitis (Liver Failure) Complicated With Infection
Status: Not yet recruiting

The goal of this observational study is to expound the population and characteristics of pathogenic microorganisms with co-infection, draw the pedigree of pathogenic microorganisms, and evaluate its influence on disease outcome in patients with severe hepatitis (liver failure). The main questions it aims to answer are:

Mapping of infectious agents in patients with severe hepatitis (liver failure)
Constructing early warning predictive models to explore how to give an individualized regimen of integrated immune function.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients agreed to participate in the study and signed an informed consent form; Sex is not limited and age is 18-70 years old; HBsAg positive for more than 6 months, or hepatitis E IgM positive, or hepatitis E RNA positive; Progressive deepening of jaundice in a short period of time (serum total bilirubin greater than 10 times the upper limit of normal or rising ≥17.1 umol/L per day); Sgnificant bleeding tendency with PTA ≤ 40% and exclusion of other non-hepatic factors.  Exclusion Criteria:  Patients with severe hepatitis caused by other non-hepatophilic viral infections; Patients who were considered by the investigator to be unsuitable for participation in the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with severe viral hepatitis (liver failure) who met the inclusion and exclusion criteria and were hospitalized in the First Hospital Affiliated to Zhejiang University School of Medicine, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing You'an Hospital Affiliated to Capital Medical University, Huashan Hospital Affiliated to Fudan University, and Qilu Hospital of Shandong University. - SamplingMethod: Non-Probability Sample
Early Intervention to Promote Cardiovascular Health of Mothers and Children
Status: Not yet recruiting

Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) is a cluster randomized clinical trial, funded by the National Heart Lung & Blood Institute. The study is designed to test the effectiveness of home visiting intervention to promote cardiovascular health and reduce disparities in maternal and early childhood cardiovascular health. Sites, in partnership with evidence-based home visiting programs, are recruiting 6400 participants in total (i.e., 3200 parent-dyads which includes 3200 parents and 3200 children) from diverse community settings with a high burden of cardiovascular disease risk factors.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Be currently enrolled in an evidence-based home visiting program participating in ENRICH Be pregnant, with a single or multifetal gestation, at or less than 34 weeks 0 days gestation (per self-report at time of consent) Be 18 years of age or older Speak English or Spanish  Exclusion Criteria: There are no exclusion criteria being applied in assessing eligibility for participation in ENRICH. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in Allergic Rhinitis
Status: Recruiting

Allergic rhinitis (AR) is a common condition, with nearly 300 million affected individuals in China, significantly impacting the quality of life. Despite standardized drug treatments, approximately 20% of AR patients experience inadequate control and require surgical intervention. AR manifests as nasal itching, sneezing, clear nasal discharge, nasal congestion, primarily associated with inflammation-induced hypertrophy of nasal turbinates and a heightened neurogenic state of the nasal mucosa. Surgical treatment focuses on "reducing hypertrophy" of nasal turbinates and "desensitizing" neurogenic hyperreactivity.High-intensity focused ultrasound (HIFU), as a minimally invasive therapeutic modality in AR, is still in its early stages of application and requires further multicenter clinical studies and widespread adoption. This project collaborates with six established institutions proficient in ultrasound treatment for AR. It aims to conduct a prospective multicenter observational study and subsequent dissemination, emphasizing the application of "reduction of hypertrophy" and "desensitization" in AR.Through standardized case selection, subjective and objective measures such as subjective symptom scores, quality of life assessments, nasal reflex, and nasal resistance tests before and after treatment will be employed to evaluate the effectiveness and safety of HIFU in "reducing hypertrophy" and "desensitizing" aspects of AR. Simultaneously, building on our established Otolaryngology Head and Neck Surgery Alliance and Southwest Allergy Alliance, the research results will be promoted through lectures, hands-on guidance, training sessions, academic conferences, and other means to facilitate the application of HIFU in AR and benefit a larger population of AR patients.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Refractory AR. Patients exhibiting persistent mucosal hypersensitivity or high secretion state (rhinorrhea, sneezing, etc.).  Exclusion Criteria:  Patients with exacerbation of nasal symptoms, uncontrolled or acute exacerbation of asthma Patients with bleeding tendency, coagulation disorders Patients with poor overall condition, unable to tolerate procedures Patients with severe cardiovascular diseases, immune system disorders, malignant tumors Patients with psychological disorders or poor compliance, combined with primary immunological diseases (such as Sjögren's syndrome) or abnormal results of tear secretion tests, etc. Patients under 18 years of age or over 70 years of age - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Alternative Application Methods of Pre-procedural Povidone Iodine Mouthrinse
Status: Recruiting

To compare the iodine remaining in saliva between gargle method and swab method

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Thai people no underlying disease, no pregnant at least 24 teeth No use iodine gargle No allergy to iodine and seafood No orthodontic and prosthetic treatment No ulcer and edentulous area Saliva flow rate in male (0.57+-0.3 ml/minute), in woman (0.41+-0.27 ml/minute) PI score lower than 0.6 (Green and vermillion index)  Exclusion Criteria:  treatment orthodontic or prosthetic treatment currently Allergy to iodine between reach Can not participate - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 30 Years - StdAgeList: Adult